Progress, Potential, and Possibilities Podcast / Show

Ira Pastor

Interviews and Discussions With Fascinating People Who are Creating A Better Tomorrow For All Of Us - Host - Ira S. Pastor

  1. 1D AGO

    Redox Biology, Aging & the Future of Beautyspan | François Vix - Founder, ISOCELL

    Send us Fan Mail For decades, the beauty industry focused on creams, serums, and surface-level solutions. But what if aging skin is really a reflection of something much deeper happening inside our cells?  Today’s guest is François Vix, a longtime global beauty and wellness executive who has spent more than four decades at the intersection of skincare science, redox biology and oxidative stress research, and healthy aging. François began his career inside some of the world’s biggest beauty and consumer health companies, holding senior leadership roles at L'Oréal, Lancôme, Biotherm, Johnson & Johnson, Neutrogena, and RoC Skincare, where he helped scale global brands across North America, Europe, Asia, and Latin America. Along the way, he became increasingly fascinated by a deeper scientific question: are we truly addressing the biological root causes of skin aging and inflammation - or simply treating the visible symptoms? That question eventually led François towards a new look at the science of redox biology, oxidative stress and the body’s endogenous antioxidant systems, particularly the enzyme Superoxide Dismutase, or SOD - one of the body’s first-line defenses against free radical damage. In 2001, François founded ISOCELL Laboratories ( https://www.glisodin.org/ ), focused on developing clinically studied approaches, including the GliSODin nutricosmetics brand, to supporting the body’s own antioxidant defense mechanisms. Over the last two decades, the company has expanded internationally into more than 50 countries and has explored applications spanning skin health, inflammation, immune function, pigmentation disorders, and longevity science. Today, François speaks widely about redox biology and oxidative stress, integrative dermatology, and what he calls “beautyspan” - the idea that the future of beauty may increasingly be tied to cellular resilience, metabolic health, and healthy aging from within. #FrançoisVix #GliSODin #OxidativeStress #FreeRadicals #Longevity #Beautyspan #AntiAging #Perimenopause #MenopauseHealth #SkinHealth #HealthyAging #Mitochondria #RedoxBiology #Antioxidants #SOD #SuperoxideDismutase #IntegrativeMedicine #FunctionalMedicine #SkinLongevity #Biohacking #Healthspan #Inflammaging #LongevityScience #BeautyScience #Hormones #WomensHealth #CellularHealth #AgingResearch #WellnessPodcast #IraPastor Support the show

    55 min
  2. 3D AGO

    The Future of Drug Delivery: From Infusion Centers to Wearable Biologics | Matthew Huddleston - Chief Commercial Officer, Enable Injections

    Send us Fan Mail Some of the most important cancer and autoimmune disease drugs in the world still require patients to sit in infusion chairs for hours - but that model may be about to change entirely. Matthew Huddleston is Chief Commercial Officer at Enable Injections ( https://enableinjections.com/ ), a medical device company focused on rethinking how large-volume biologic drugs are delivered to patients. Enable’s core technology, the enFuse® on-body delivery system, is designed to shift certain therapies from traditional intravenous infusion to subcutaneous, wearable administration - potentially transforming treatment from something that requires a clinic visit into something that can be done at home, more comfortably and more conveniently. What makes this particularly interesting is where Enable sits in the broader biopharma ecosystem. The company is actively partnering with major pharmaceutical innovators including Sanofi, Roche, Incyte, and Viridian Therapeutics to support the transition of complex biologics into subcutaneous delivery formats. One of the clearest signals of momentum is that Sanofi’s Sarclisa combined with Enable’s on-body injector has been recommended for approval in Europe by the CHMP, with FDA review ongoing - highlighting that this is no longer theoretical innovation, but an emerging commercial pathway. Enable is also extending its platform through collaboration with Aptar Pharma and its digital health division, integrating companion software to support patients throughout therapy - bringing drug delivery closer to a connected care ecosystem, where device, data, and treatment adherence increasingly converge. On this episode we will unpack how this platform works, what it enables for pharma partners, and how wearable drug delivery could reshape the future of biologics. #biotech #medtech #drugdelivery #biologics #pharma #oncology #multiplemyeloma #medicaldevices #healthtech #wearabletech #subcutaneous #infusiontherapy #drugdevelopment #pharmaceuticalindustry #innovation #digitalhealth #enableinjections #sanofi #roche #incyte #clinicaltrials Support the show

    36 min
  3. 5D AGO

    How argenx Is Reinventing Autoimmune Treatment | Dr. Luc Truyen, M.D., Ph.D., Chief Medical Officer, argenx

    Send us Fan Mail Most autoimmune drugs suppress the immune system broadly - but what if you could selectively remove the antibodies actually causing disease? That’s exactly what VYVGART is doing, and it may fundamentally change how we treat conditions like myasthenia gravis and CIDP. Dr. Luc Truyen, M.D., Ph.D., is Chief Medical Officer at argenx ( https://argenx.com/ ), where he leads the company’s global clinical development and medical strategy across a rapidly advancing portfolio of immunology and neuromuscular therapies. A neurologist by training, Dr. Truyen brings more than two decades of experience in drug development, with a particular focus on neuroscience, neuroimmunology, and complex CNS disorders. Before joining argenx in 2021, he spent over 20 years at Johnson & Johnson and its pharmaceutical division Janssen Pharmaceuticals, where he held multiple senior leadership roles. Most notably, Dr. Truyen served as Global Head of Development for Neuroscience at Janssen, overseeing early- and late-stage pipelines spanning mood disorders, schizophrenia, and neurodegenerative and neuroinflammatory diseases. He also led global external affairs efforts in Alzheimer’s disease, playing key roles in major international collaborations such as the Innovative Medicines Initiative and global dementia platforms. Earlier in his career, Dr. Truyen was Head of R&D and Chief Medical Officer of Janssen Alzheimer Immunotherapy, where he helped guide strategy across research, clinical development, and regulatory functions for novel immunotherapies targeting Alzheimer’s disease. At argenx, Dr. Truyen is now helping drive the expansion of VYVGART (efgartigimod), a first-in-class FcRn antagonist, across multiple indications including myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP), while advancing a broader pipeline aimed at transforming treatment paradigms in autoimmune and neuromuscular diseases. Dr. Truyen earned both his M.D. and Ph.D. in Neurology from the University of Antwerp. #LucTruyen #argenx #VYVGART #efgartigimod #MyastheniaGravis #CIDP #AutoimmuneDisease #Neurology #Biotech #Pharma #DrugDevelopment #FcRn #Immunology #RareDisease #ClinicalTrials #AAN2026 #MedicalInnovation #HealthcareInnovation #BiotechPodcast #LifeSciences #Neuroimmunology #IVIG #PrecisionMedicine #FutureOfMedicine Support the show

    29 min
  4. 6D AGO

    Reversing Humanity’s #1 Killer - Arterial Plaque | Dr. Matthew O’Connor, Ph.D. - CEO and Co-Founder - Cyclarity Therapeutics

    Send us Fan Mail In the time it will take you watch this episode, over 2,000 people around the world will die from diseases driven by arterial plaque. But what if we could actually remove the toxic cholesterol already trapped inside arteries? Today we’re diving into one of the biggest unsolved problems in medicine and aging: how do you actually remove arterial plaque instead of merely slowing its progression? Cardiovascular disease remains the world’s leading killer, despite decades of statins, anti-inflammatory drugs, and newer RNA-based therapies. Most existing treatments help manage cholesterol and reduce risk, but very few directly target the toxic debris already embedded inside plaques. But what if we could literally extract some of the most dangerous oxidized cholesterol molecules from the body? My guest today is Dr. Matthew ‘Oki’ O’Connor, Ph.D. - CEO and Co-Founder of Cyclarity Therapeutics ( https://cyclaritytx.com/ ), a biotech company developing engineered cyclodextrin molecules designed to bind and remove 7-ketocholesterol, or 7KC - a toxic oxidized cholesterol strongly implicated in atherosclerosis, inflammation, plaque instability, and even broader age-related diseases. Just recently, the company presented first-in-human clinical data at the American Heart Association Vascular Discovery Scientific Sessions showing dose-dependent urinary excretion of 7KC - potentially the first clinical evidence that this toxic molecule can be safely mobilized and removed from the human body. We’ll discuss what 7KC actually is, why oxidized cholesterol may be a root driver of cardiovascular disease, how engineered cyclodextrins work like molecular “sponges,” what the new human data really shows - and what it would mean if medicine could move from slowing plaque progression to truly reversing it. #HeartDisease #Atherosclerosis #Longevity #CardiovascularDisease #PlaqueReversal #AgingResearch #Biotech #Cholesterol #OxidizedCholesterol #7Ketocholesterol #Cyclarity #Healthspan #PrecisionMedicine #AIinBiotech #DrugDiscovery #PreventiveMedicine #Cardiology #AntiAging #Lifespan #MedicalInnovation #SENS #FoamCells #Plaque #HeartAttack #StrokePrevention Support the show

    47 min
  5. 6D AGO

    Fixing the $100B Fluid Overload Crisis in Heart & Kidney Disease | Ryan Marthaler - Vice President of Product Marketing and Business Development, Nuwellis

    Send us Fan Mail One of the biggest drivers of hospital admissions isn’t what most people think - it’s fluid. Not infection, not surgery…fluid overload. And when the body stops responding to diuretics, medicine runs into a wall. Today we’re exploring one of the most challenging and underappreciated frontiers in hospital medicine: fluid overload and the cardiorenal continuum - where heart failure and kidney dysfunction intersect in ways that dramatically affect outcomes, costs, and quality of life. Our guest is Ryan Marthaler, Vice President of Product Marketing and Business Development at Nuwellis, Inc. ( https://nuwellis.com/ ), a medical technology company focused on integrated fluid management solutions for both adult and pediatric patients. Ryan brings a two-decade career spanning Medtronic, St. Jude Medical, and digital health innovation - working at the intersection of clinical evidence, commercial strategy, and product development. At Nuwellis, he has helped drive a strategic shift toward earlier intervention in fluid management and stronger evidence-based commercialization. We’ll be discussing the company’s core therapy platform, including the Aquadex SmartFlow System, a controlled ultrafiltration system designed to remove excess fluid in patients with fluid overload who are unresponsive to diuretics. Beyond the technology, this conversation is really about a bigger question: How do we better manage fluid balance across the heart-kidney axis - and what happens when we intervene earlier, more precisely, and more consistently? #HeartFailure #CardiorenalSyndrome #FluidOverload #HealthcareInnovation #MedicalDevices #CriticalCare #Nephrology #Cardiology #HospitalMedicine #MedTech #Ultrafiltration #KidneyDisease #ICU #HealthTech #HealthcareEconomics #MedicalInnovation Support the show

    34 min
  6. MAY 19

    Pharma’s Biggest Blind Spot: Why 99.9% of Chemical Space Was Never Explored | Dr. Olga Nissan, Ph.D. - Vice President of Business Development, Evogene

    Send us Fan Mail Pharma has only explored a tiny fraction - less than one-tenth of one percent - of all possible drug-like molecules. So the question is: what happens when AI suddenly opens up the other 99.9%? Dr. Olga Nissan, Ph.D. is Vice President of Business Development at Evogene ( https://evogene.com/ ) where she leads pharmaceutical partnerships for the company’s ChemPass AI generative chemistry platform - an advanced system designed to dramatically expand the searchable universe of drug-like molecules. With over 15 years of experience spanning biotech, pharma, and computational biology, Dr. Nissan operates at the intersection of science, strategy, and commercialization. Prior to Evogene, she was Co-Founder and CEO of Protica Bio, a precision oncology company focused on translating novel biological insights into therapeutic opportunities. Earlier in her career, she held scientific and operational roles at Teva Pharmaceutical Industries, as well as EcoPhage and BiomX, building expertise across microbiology, molecular biology, and translational R&D. Dr. Nissan has a strong track record of advancing technologies from early discovery through clinical and commercial partnerships, and of aligning cutting-edge innovation with the practical needs of pharmaceutical companies. She earned her Ph.D. and completed her postdoctoral training at the Weizmann Institute of Science. #DrugDiscovery #AIinPharma #GenerativeAI #Biotech #PharmaInnovation #ChemistryAI #MachineLearning #DrugDevelopment #PharmaceuticalIndustry #Bioinformatics #AIResearch #ChemPass #Evogene #ComputationalChemistry #FutureOfMedicine #DrugDesign #DeepLearning #HealthcareInnovation #BiotechNews #SciencePodcast Support the show

    44 min
  7. MAY 18

    Programming Biology: Inside the DNA Supply Chain Powering Modern Drug Discovery - Dr. Patrick Finn, Ph.D. - President & COO -Twist Bioscience

    Send us Fan Mail We used to think of DNA as something we read. Now we’re starting to treat it like something we write - and that changes everything about how medicine gets made. Dr. Patrick Finn, Ph.D. is President and COO of Twist Bioscience ( https://www.twistbioscience.com/ ), a company that’s helping turn biology into something you can engineer, iterate, and even industrialize.  Dr. Finn has spent his entire career building the infrastructure layer of modern biotech - from sequencing and sample prep at Beckman Coulter and Invitrogen, to scaling commercial platforms at Agilent Technologies and now Twist. Dr. Finn also served as Vice President of Sales and Marketing for Enzymatics (recently acquired by QIAGEN), leading commercial activities for North America and Europe, delivering significant top line growth and expanding the base of business to business customers. So this isn’t just a conversation about the future - it’s about how the tools that make the future possible are actually built and deployed. On this episode we go beyond the buzzwords and dig into what it really means to “program biology”, and how close we actually are to designing medicines the way we design software. In addition to his role at Twist, Dr. Finn currently serves on the Scientific Advisory Board of Lasergen and previously served on the Scientific Advisory Board of Enzymatics. He holds a PhD in Nucleic Acid Chemistry from Southampton University and a BSc Hons in Chemistry from Heriot-Watt University. #SyntheticBiology #Biotech #DrugDiscovery #AIinHealthcare #ArtificialIntelligence #DNA #Genomics #Bioengineering #ProgrammableBiology #CRISPR #GeneTherapy #Biotechnology #LifeSciences #MachineLearning #AIResearch #PharmaInnovation #Biology #SciencePodcast #FutureOfMedicine #Biodesign #SyntheticDNA #GenomeSequencing #Bioeconomy #DeepTech #HealthTech Support the show

    51 min
  8. MAY 18

    The Future of Aging: From Healthspan to Joyspan | Dr. Sanjay Shetty, MD - President, CenterWell/Humana & Dr. Kerry Burnight, Ph.D. - Author, Joyspan

    Send us Fan Mail For decades, medicine focused on helping us live longer. Then came healthspan - helping us stay healthier longer. But what if the next frontier is something even deeper: joyspan… the quality, meaning, and fulfillment of the years we actually live? Today’s conversation sits at the intersection of healthcare delivery, aging science, and one of the most important - and perhaps least discussed - questions in modern medicine: How do we help people not simply live longer… but live fulfilled lives? For decades, healthcare systems have largely measured success through clinical outcomes - lowering blood pressure, reducing hospitalizations, extending survival curves. But as populations age and chronic disease becomes increasingly intertwined with loneliness, purpose, financial security, cognition, and emotional well-being, a much broader picture of health is emerging. And that broader picture is exactly what we explore on this episode. Joining us is Dr. Sanjay Shetty, MD, President of CenterWell ( https://www.centerwell.com/ ) and a senior leader at Humana ( https://www.humana.com/ ).  Dr. Shetty has one of the most fascinating and diverse backgrounds in modern healthcare - physician, radiologist, Harvard Medical School faculty member, Bain healthcare strategist, hospital system operator, value-based care leader, and now the executive overseeing one of America’s largest senior-focused healthcare platforms spanning primary care, home health, pharmacy, and military health services. Under Dr. Shetty's leadership, CenterWell has increasingly focused on the idea that healthcare for older adults must move beyond episodic medicine and toward deeply integrated, personalized, and human-centered care. We’re also joined by Dr. Kerry Burnight, Ph.D. ( https://drkerryburnight.com/ ) - gerontologist, educator, elder justice advocate, and author of the bestselling book Joyspan ( https://www.amazon.com/Joyspan-Science-Thriving-Lifes-Second/dp/1546007350 ).  Dr. Burnight has spent decades studying aging not as decline, but as a stage of life that can be rich with purpose, connection, growth, and meaning. Her work challenges the fear-driven “anti-aging” narrative and introduces the concept of “joyspan” - the quality, vitality, and emotional richness of the years we live. Together, our guests bring two critically important perspectives: one from the operational front lines of transforming healthcare delivery for millions of seniors…and the other from the psychological, emotional, and social science of what actually makes later life meaningful. Part of today’s discussion will center around a fascinating new CenterWell/Humana report titled Understanding Fulfillment for Older Adults: Definition and Impact ( https://assets.humana.com/is/content/humana/CenterWell%20Understanding%20Fulfillment%20in%20Older%20Adultspdf ), which examined more than 5,500 Americans over age 62 and attempted to quantify something medicine rarely measures directly: fulfillment. The findings are remarkable: that fulfillment in later life is influenced less by traditional clinical variables alone and more by factors like self-contentment, purpose, optimism, gratitude, emotional connection, and feeling appreciated by others. So on this episode, we ask: - Can healthcare systems measure fulfillment? - Should fulfillment become a clinical endpoint? - What happens when longevity medicine evolves from merely extending lifespan… to supporting joyspan? - And how do we redesign healthcare, communities, technologies, and even culture itself around what older adults actually value most? #Aging #Longevity #Healthspan #Joyspan #Fulfillment #CenterWell #Humana #SanjayShetty #KerryBurnight #HealthyAging #SeniorCare #FutureOfHealthcare #Gerontology #Loneliness #ValueBasedCare #HealthcareInnovation #PrecisionHealth #AgingWell #HealthcareTransformation #OlderAdults #LongevityScience #Purpose #Wellbeing #HomeHealthcare #PPPShow Support the show

    57 min

Ratings & Reviews

5
out of 5
6 Ratings

About

Interviews and Discussions With Fascinating People Who are Creating A Better Tomorrow For All Of Us - Host - Ira S. Pastor

You Might Also Like